ClinicalTrials.gg
CompletedNCT05516407Updated Sep 8, 2026

Safety and Efficacy of Oral Full-Spectrum Medicinal Cannabis Plant Extract in Children With Autism Spectrum Disorder.

A Phase 1/2 interventional study of FEN164 in Autism Spectrum Disorder, sponsored by Fenix Innovation Group. Completed at 1 site in Australia. Open to participants aged 8 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-09-08.

Sponsored by Fenix Innovation Group · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year after the study started (first participant enrolled Apr 2021, registered Apr 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
18
Allocation
Not applicable
Ages
8 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies in Autism Spectrum Disorder with a site in Australia — 4 open to participants now, 5 under way, 2 of them phase 3. Autism Spectrum Disorder · Australia.

Enrollment
17th of 17
18 · median 120
Started
2021
with 4 others
Phase 1/2
Only one
of the 22
Registered
13th of 22
by date
Lead sponsor
3 of 22
Fenix Innovation Group

Among the 22 studies in Autism Spectrum Disorder with a site in Australia, this one is the 17th largest by enrollment of the 17 interventional ones that give a count, is one of 5 that started in 2021, is the only one in phase 1/2, and was the 13th registered.

Autism Spectrum Disorder

1,728 studies on the registry are indexed under Autism Spectrum Disorder; 501 are open to participants now.

Browse Autism Spectrum Disorder studies →

Open to participants now

4 of the 22 studies in Autism Spectrum Disorder with a site in Australia are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 350 Autism Spectrum Disorder studies recruiting now, 48 (14%) set no upper age limit and 295 (84%) stop at 75 or younger; 299 take children under 18; 92 take healthy volunteers.

This study: 8 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Autism Spectrum Disorder with a site in Australia, or all of them as a file.
02

Study summary

This is a 20-week open-label study to evaluate the safety and efficacy of full-spectrum medicinal cannabis plant extract \< 0.08% THC (FEN164) in children with Autism Spectrum Disorder.

Read the detailed description

The study population will include twenty (20) boys and girls aged eight (8) years through to seventeen (17) years that have a medical diagnosis of Level 2 and 3 Autism Spectrum Disorder (ASD) as confirmed by the Autism Diagnostic Observational Schedule (ADOS-2) criteria.

Participants will commence treatment with a daily dose of 5mg/kg of FEN164. This will gradually increase over a four-week period until the maximum tolerated daily dose or 20mg/kg per day is achieved (Up-titration phase/Stage 1). Participants will continue to receive their respective maximum dose for eight (8) weeks (Treatment phase/Stage 2) which will be gradually decreased by 5 mg/kg for a period of 4 weeks until the end of the study (Down-titration phase).

03

Conditions studied

  • Autism Spectrum Disorder
04

Who can participate

Ages eligible
8 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant is aged 8 years to 17 years (inclusive)
  • Participant is at a healthy weight at the discretion of the Principal Investigator.
  • Parents or caregivers can give for participation in the trial with assent from individuals with autism.
  • Participants can comply with trial requirements.
  • According the , 5th Edition (DSM-5) criteria the participant has a diagnosis of Level 2 or 3 Autism Spectrum Disorder (ASD) confirmed by Autism Diagnostic Observational Schedule (ADOS-2) criteria
  • All treatments including medications and therapies for ASD related symptoms must have been stable for 4 weeks before enrolment and for the duration of the trial wherever possible.
  • Participants must be able to swallow liquid.
  • Consent giver must be able to understand the requirements of the study.

Exclusion criteria

Exclusion Criteria:

  • Current diagnosis of bipolar disorder, psychosis, schizophrenia, schizoaffective disorder, or active major depression
  • Has a diagnosis other than ASD that dominates the clinical presentation (e.g., Attention Deficit Hyperactivity Disorder [ADHD])
  • Has a degenerative condition
  • Changes in anticonvulsive therapy within the last 12 weeks
  • Taking omeprazole, lansoprazole, tolbutamide, warfarin, sirolimus, everolimus, temsirolimus, tacrolimus, clobazam, repaglinide, pioglitazone, rosiglitazone, montelukast, bupropion, or efavirenz
  • Currently using or has used recreational or medicinal cannabis, cannabinoid-based medications (including Sativex®, or Epidiolex®) within the 12 weeks prior to screening and is unwilling to abstain for the duration of the trial
  • Participant has any known or suspected to cannabinoids or any of the
  • Participant has moderately impaired hepatic function at screening, defined as serum (ALT) or aspartate aminotransferase (AST) > 2 × (ULN) or total (TBL) > 2 × ULN. This criterion can only be confirmed once the laboratory results are available; participants enrolled into the trial who are later found to meet this criterion must be screen-failed.
  • Participant is male and fertile (i.e., after puberty unless permanently sterile by bilateral orchidectomy) unless willing to ensure that they use male (condom) or remain sexually abstinent during the trial and for 12 weeks thereafter.
  • Participant is female and with (i.e., following menarche and until becoming for ≥ 12 consecutive months unless permanently sterile by hysterectomy, bilateral salpingectomy, or bilateral oophorectomy) unless willing to ensure that they use a highly effective method of birth control (e.g., hormonal contraception, intrauterine device/hormone-releasing system, bilateral tubal occlusion, vasectomized partner, sexual abstinence) during the trial and for 12 weeks thereafter.
  • Female participant who is pregnant (positive pregnancy test), lactating or planning pregnancy during the course of the trial or within 12 weeks thereafter.
  • Participant had brain surgery or traumatic brain injury within 1 year of screening.
  • Participant has any other significant disease or disorder which, in the opinion of the investigator, may either put the participant, other participants, or site staff at risk because of participation in the trial, may influence the result of the trial, or may affect the participant's ability to take part in the trial.
  • Any abnormalities identified following a physical examination of the participant that, in the opinion of the investigator, would jeopardize the safety of the participant if they took part in the trial
  • Any history of suicidal behaviour (lifelong) or any suicidal ideation of type 4 or 5 on the Columbia-Suicide Severity Rating Scale (C-SSRS) in the last 4 weeks or at screening or randomization
  • Participant has donated blood during the past 12 weeks and is unwilling to abstain from donation of blood during the trial.
  • Participant has any known or suspected history of alcohol or substance abuse or positive drugs of abuse test at screening (not justified by a known concurrent medication).
  • Participant has previously been enrolled into this trial.
  • Participant has plans to travel outside their country of residence during the trial, unless the participant has confirmation that the product is permitted in the destination country/state
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    FEN164

    Full-Spectrum Medicinal Cannabis Plant Extract with less than 0.08% THC (FEN164) Stage 1: 5mg/kg, 10mg/kg, 15mg/kg, 20mg/kg (1 week each) Stage 2: 20mg/kg (8 weeks), 15mg/kg, 10mg/kg, 5mg/kg (1 week each)

    Drug: FEN164

Interventions

  • DrugFEN164

    Oil based. Full-spectrum medicinal cannabis plant extract with less than 0.08% THC.

06

What researchers measure

Primary outcomes

  1. Clinical Global Impression Scale - Improvement (CGI-I)

    This is a 7-point scale measuring symptom change from baseline. Where a score of 1 is very much improved and a score of 7 is very much worse.

    Time frame: Baseline, Weeks 5, 9, 13 & 17

Secondary outcomes

  1. Vineland Adaptive Behaviour Scales, Third Edition

    Used to measure adaptive functioning across three core domains (Communication, Daily Living Skills, and Socialization), and two optional domains (Motor Skills and Maladaptive Behaviour); items are rated on a 3-point scale (0=never; 1=sometimes; 2=usually or often). The core domains sum to a total Adaptive Behaviour Composite.

    Time frame: Baseline, Week 17

  2. Social Responsiveness Scale, 2nd Editions (SRS-2)

    Five domains are assessed including: Social Awareness, Social Cognition, Social Communication, Social Motivation, and Restricted Interests and Repetitive Behaviour. Items are scored on a 4-point scale (ranging from 1=not true to 4=almost always true).

    Time frame: Baseline, Week 17

  3. Anxiety, Depression and Mood Scale (ADAMS)

    28 symptom items that resolve into five subscales labelled: Manic/Hyperactive Behaviour, Depressed Mood, Social Avoidance, General Anxiety, and Compulsive Behaviour. Items are rated on 4-point scale ranging from 0=not a problem to 3=severe problem.

    Time frame: Baseline, Week 17

  4. Sleep Disturbance Scale for Children (SDSC)

    Six subscales including Disorders of Initiating and Maintaining Sleep, Sleep Breathing Disorders, Disorders of Arousal, Sleep Wake Transition Disorders, Disorders of Excessive Somnolence, and Sleep Hyperhydrosis. Items are rated on 5-point scale where 1=never and 5=always (daily). Subscale scores sum to equal a total score.

    Time frame: Baseline, Weeks 5, 9, 13 & 17

  5. Clinical Global Impression-Severity (CGI-S)

    Reflects clinician's impression of severity of illness on a 7-point scale ranging from 1=not at all to 7=among the most extremely ill.

    Time frame: Baseline, Weeks 5, 9, 13 & 17

  6. Autism Family Experience Questionnaire (AFEQ)

    Parent/Caregiver form used to measure impact of autism interventions on family experience and quality of life. Items are rated on a 5-point scale where 1=always and 5=never.

    Time frame: Baseline, Week 17

  7. Anxiety Scale for Children - Autism Spectrum Disorder - Parent Version (ASC-ASD-P)

    Parent/Caregiver form developed to detect symptoms of anxiety in youth with ASD. Composed of four subscales (Performance Anxiety, Uncertainty, Anxious Arousal, and Separation Anxiety), items are rated on a 4-point scale (0=never and 3=always). Subscales sum to equal a total score.

    Time frame: Baseline, Weeks 5, 9, 13 & 17

  8. Anxiety Scale for Children - Autism Spectrum Disorder - Child Version (ASC-ASD-C)

    Child form developed to detect symptoms of anxiety in youth with ASD. Composed of four subscales (Performance Anxiety, Uncertainty, Anxious Arousal, and Separation Anxiety), items are rated on a 4-point scale (0=never and 3=always). Subscales sum to equal a total score.

    Time frame: Baseline, Weeks 5, 9, 13 & 17

  9. The Child Behaviour Checklist for Ages 6 - 18 (CBCL)

    A parent/carer measure to assess patterns of behaviour. The measure is a Likert scale rated over 3 or 4 points.

    Time frame: Baseline, Week 17

  10. Caregiver Global Impression of Change in Attention (CGI-CA)

    Reflects clinician's impression of change in attention on a 7-point scale ranging from 1=not at all to 7=very severe problem. Provided as Baseline and Post-Baseline questionnaires.

    Time frame: Baseline, Weeks 5, 9, 13 & 17

  11. Caregiver Global Impression of Change (CGI-C) Target Behaviour

    Reflects clinician's impression of change of behaviour on a 7-point scale ranging from 1=not at all to 7=very severe problem. Provided as Baseline and Post-Baseline questionnaires.

    Time frame: Baseline, Weeks 5, 9, 13 & 17

07

Study locations

1 site
  • Monash Children's Hospital
    Clayton, Victoria 3168, Australia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2021 to primary completion in Sep 2022, 17 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 4, 2022
First posted
Aug 25, 2022
StartActual
Apr 1, 2021
Primary completionActual
Sep 1, 2022
CompletionActual
Aug 28, 2026
Last update
Sep 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05516407
Lead sponsor
Fenix Innovation Group
Collaborators
Neurotech International Limited, Monash Health
Responsible party
Sponsor
First posted
Aug 25, 2022
Start date
Apr 1, 2021
Primary completion
Sep 1, 2022
Completion
Aug 28, 2026
Last update
Sep 8, 2026

Study contacts

Michael Fahey
principal investigator · Head of Paediatric Neurology

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion